â€¢   higher employee termination costs a result of the acquisition of an irish biologic therapeutics company in the third quarter of 2017, initiatives to better align our organizational structure in europe, and our operational efficiency initiative and supply network strategy, and
(g)   represents charges incurred for restructuring and cost-reduction/productivity initiatives. for 2017, charges are related to employee termination costs in europe as a result of initiatives to better align our organizational structure.